Malignant melanoma in early Parkinson's disease: The DATATOP trial

Movement Disorders

Volumn 22, Issue 5, 2007, Pages 720-722

  Constantinescu, Radu ^a   Romer, Megan ^a   Kieburtz, Karl ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Levodopa; Malignant melanoma; Parkinson's disease

Indexed keywords

ALPHA TOCOPHEROL; LEVODOPA; SELEGILINE;

ADULT; AGED; ARTICLE; CANCER RISK; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MORBIDITY; MULTICENTER STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; COHORT STUDIES; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INCIDENCE; LEVODOPA; MALE; MELANOMA; MIDDLE AGED; MULTICENTER STUDIES; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS; REFERENCE VALUES; RETROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 34249073067     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21273     Document Type: Article

References (15)

1. Jansson B, Jankovic J. Low cancer rates among patients with Parkinson's disease. Ann Neurol 1985;17:505-509.
2. Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Moller H. Atypical cancer pattern in patients with Parkinson's disease. Br J Cancer 2005;92:201-205.
3. Elbaz A, Peterson BJ, Bower JH, et al. Risk of cancer after the diagnosis of Parkinson's disease: a historical cohort study. Mov Disord 2005;20:719-725.
4. Vanacore N, Spila-Alegiani S, Raschetti R, Meco G. Mortality cancer risk in parkinsonian patients: a population-based study. Neurology 1999;52:395-398.
5. Moller H, Mellemkjaer L, McLaughlin JK, Olsen JH. Occurrence of different cancers in patients with Parkinson's disease. BMJ 1995;310:1500-1501.
6. Skibba JL, Pinckley J, Gilbert EF, Johnson RO. Multiple primary melanoma following administration of levodopa. Arch Pathol 1972;93:556-561.
7. Physicians' desk reference. 60th ed. Montvale, NJ: Thomson PDR; 2006. p 3111.
8. Fiala KH, Whetteckey J, Manyam BV. Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence? Parkinsonism Relat Disord 2003;9:321-327.
9. Siple JF, Schneider DC, Wanlass WA, Rosenblatt BK. Levodopa therapy and the risk of malignant melanoma. Ann Pharmacother 2000;34:382-385.
10. Wick MM, Byers L, Frei E III. L-dopa: selective toxicity for melanoma cells in vitro. Science 1977;197:468-469.
11. Gurney H, Coates A, Kefford R. The use of L-dopa and carbidopa in metastatic malignant melanoma. J Invest Dermatol 1991;96:85-87.
12. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. Arch Neurol 1989;46:1052-1060.
13. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
14. SEER Cancer Statistics Review 1975-2002, Table XVI-2, Melanoma of the skin (invasive), 1998-2002. Available at: http://seer.cancer.gov/resources/. Accessed September 9, 2005.
15. Edwards SJ, Lilford RJ, Braunholtz DA, Jackson JC, Hewison J, Thornton J. Ethical issues in the design and conduct of randomised controlled trials. Health Technol Assess 1998;2:i-vi, 1-132.